Primary biliary cholangitis: diagnosis, UDCA therapy, and treat-to-target

What primary biliary cholangitis is

Primary biliary cholangitis (PBC) is a chronic, organ-specific autoimmune liver disease. The immune system directs T-cells against the epithelial cells lining the small interlobular bile ducts inside the liver — the tiny channels that collect bile from liver cells. This progressive inflammatory attack destroys those ducts, reduces bile flow, and causes cholestasis. Over time, accumulated toxic bile acids and chronic inflammation produce periportal fibrosis and, in untreated disease, biliary cirrhosis.

The name was updated from “primary biliary cirrhosis” to “primary biliary cholangitis” in 2015, because the majority of patients now diagnosed with modern testing have no cirrhosis — they are caught at an earlier, non-cirrhotic stage.

PBC is overwhelmingly a disease of women (approximately 9:1 female-to-male), with peak presentation at age 50–60 years. Australian prevalence is approximately 40 per 100,000, with rising detection from routine biochemistry. About 50% of patients are asymptomatic at diagnosis, identified only because an alkaline phosphatase (ALP) elevation is found on a blood count ordered for another reason.

A. Core clinical — the AU general practice framework

Recognising PBC in general practice

The typical finding that triggers investigation is an isolated or disproportionately elevated ALP — the cholestatic pattern: ALP and GGT elevated, ALT and AST normal or only mildly raised, bilirubin normal in early disease.

Symptomatic presentations:

• Fatigue (50–80%) — often severe and disproportionate to liver test results; responds poorly to UDCA; the dominant quality-of-life burden
• Pruritus (20–70%) — generalised, often worse at night, palms and soles are commonly affected; may predate the diagnosis by years; does not respond to antihistamines
• Sicca symptoms (dry eyes, dry mouth) from frequent Sjögren’s syndrome overlap
• Right upper quadrant ache — vague, intermittent, in approximately 15%
• Late features — jaundice, ascites, variceal haemorrhage, encephalopathy (advanced disease only)

Autoimmune associations found in about half of PBC patients: Sjögren’s syndrome (~70%), autoimmune thyroid disease (~20%), Raynaud’s phenomenon, systemic sclerosis (CREST), coeliac disease, rheumatoid arthritis.

Diagnostic criteria

Diagnosis of PBC requires two of three (AASLD 2019; EASL 2017):

1. Persistent cholestatic biochemistry (ALP >1.5× ULN, ± GGT) for at least six months
2. Anti-mitochondrial antibody (AMA or AMA-M2) positive at titre ≥1:40 — sensitivity ~95%, specificity ~98%
3. Compatible liver histology — granulomatous cholangitis affecting small bile ducts

Liver biopsy is not routinely required when AMA-positive with classic cholestatic biochemistry. Biopsy is reserved for AMA-negative cases, suspected AIH overlap, or atypical biochemistry.

In AMA-negative PBC (approximately 5%), look for PBC-specific ANA patterns — sp100 (nuclear dot pattern) and gp210 (nuclear rim pattern). These antibodies, when positive, confirm the diagnosis and are associated with a worse prognosis compared with AMA-positive disease.

Initial investigations

In general practice before hepatology referral:

• LFTs (ALP, GGT, ALT, AST, bilirubin, albumin, INR)
• FBC — thrombocytopenia suggests portal hypertension
• Immunoglobulins — elevated IgM is characteristic of PBC; elevated IgG suggests AIH overlap
• AMA / AMA-M2 autoantibody
• ANA panel including sp100 and gp210 (request from laboratory as PBC-specific ANA patterns)
• Lipid profile — cholesterol is typically markedly elevated in PBC, but is lipoprotein-X, which is non-atherogenic; cardiovascular risk is not increased despite high total cholesterol
• Vitamin D, calcium — baseline for bone health
• TFTs — autoimmune thyroid disease is a common overlap
• Coeliac serology (anti-tTG IgA + total IgA)
• HBsAg, anti-HCV — exclude viral hepatitis
• Liver ultrasound — exclude biliary obstruction, assess for splenomegaly, baseline measurement

Mimics to exclude: primary sclerosing cholangitis (normal extrahepatic biliary tree on imaging in PBC; MRCP distinguishes), autoimmune hepatitis (elevated IgG, interface hepatitis, ANA/ASMA positive), drug-induced cholestasis, haemochromatosis (ferritin + transferrin saturation + HFE genotyping), Wilson disease (caeruloplasmin if under 40), alpha-1-antitrypsin deficiency.

B. Evidence for treatment and treat-to-target

UDCA — first-line and lifelong

Ursodeoxycholic acid (UDCA) 13–15 mg/kg/day in two to four divided doses is first-line treatment for all patients with PBC, regardless of disease stage (eTG; AASLD 2019; EASL 2017).

The combined analysis of UDCA trials (Poupon, NEJM 1997) demonstrated that UDCA significantly reduces ALP and bilirubin, delays histological progression, and extends transplant-free survival. UDCA is PBS-listed and is taken indefinitely. It is safe in pregnancy.

Treat-to-target at 12 months

At 12 months on UDCA, biochemical response is assessed using validated tools to stratify transplant risk and decide whether second-line therapy is needed:

• Paris II criteria (Corpechot, J Hepatol 2011) — adequate response requires ALL THREE: ALP ≤1.5× ULN, AST ≤1.5× ULN, and bilirubin ≤1× ULN at 12 months
• GLOBE score (Lammers, Gastroenterology 2015) — integrates age, bilirubin, ALP, albumin, and platelet count; score above 0.30 predicts significantly reduced 10-year transplant-free survival
• UK-PBC risk score (Carbone, J Hepatol 2016) — predicts 5/10/15-year transplant-free survival

Patients failing the 12-month treat-to-target criteria require second-line therapy — refer to hepatology if not already established.

Second-line therapy

Obeticholic acid (OCA, Ocaliva) 5–10 mg/day — farnesoid-X receptor agonist; POISE trial (Nevens, NEJM 2016) showed significant ALP normalisation and bilirubin reduction when added to UDCA in inadequate responders; available on PBS (TGA Authority Restricted for UDCA-inadequate PBC); monitor for pruritus worsening and dose-reduce in cirrhosis.

Bezafibrate 400 mg/day — fibrate repurposed as a nuclear receptor agonist improving biliary secretion; BEZURSO trial (Corpechot, NEJM 2018) demonstrated normalisation of liver function tests in 67% of UDCA-non-responders versus 0% placebo; not PBS-listed for PBC (off-label); hepatology-supervised use; avoid in renal impairment.

C. Managing symptoms — the pruritus ladder

Pruritus is the most distressing symptom of PBC and does not respond to antihistamines (which target histamine-driven itch, not cholestatic itch).

Pruritus treatment ladder per eTG and AASLD 2019:

1. Cholestyramine 4–16 g/day (anion-exchange resin) — binds bile salts in the gut, reducing enterohepatic recirculation; separate dosing from UDCA and other medications by at least two hours before and four hours after (binds other drugs)
2. Rifampicin 150–300 mg twice daily — induces hepatic CYP enzymes to modify bile-acid metabolism; effective but monitor LFTs (hepatotoxicity in ~5%); drug interactions (warfarin, OCP, antiepileptics)
3. Naltrexone 25–50 mg daily or naloxone — opioid receptor antagonist targets the endogenous opioid-pruritus pathway; effective but may precipitate opioid withdrawal in dependence
4. Sertraline 50–100 mg daily — modest evidence; reasonably well-tolerated

Severe refractory pruritus is a quality-of-life indication for listing for liver transplantation regardless of liver function — discuss with hepatology.

Fatigue in PBC is multifactorial and often does not respond to UDCA or treatment of the underlying liver disease. Assess and manage sleep disturbance, anaemia, hypothyroidism, and depression. Supervised exercise programmes modestly improve fatigue. Ensure no sedating medications that worsen the symptom.

D. Australian operations

MBS and PBS

• Standard consults — 23/36/44
• LFTs, immunoglobulins, autoantibody panel — standard pathology items
• DEXA — 12306
• GP Chronic Condition Management Plan — 965/967 for ongoing multidisciplinary shared care
• UDCA — PBS General Schedule (requires specialist confirmation of diagnosis initially)
• Obeticholic acid — PBS Authority Restricted (specialist prescription; UDCA-inadequate PBC)
• Cholestyramine, rifampicin, naltrexone — PBS General Schedule

Monitoring schedule (shared care)

• 3-monthly — LFTs on UDCA during first year; watch ALP and bilirubin trajectory
• 12-month — formal treat-to-target assessment using GLOBE/UK-PBC/Paris II; decide second-line
• Annually — full LFTs, albumin, INR, bilirubin, vitamin D, TSH, DEXA, liver ultrasound
• 6-monthly ultrasound ± AFP if cirrhotic (HCC surveillance)
• Variceal screen — upper GI endoscopy if liver stiffness ≥20 kPa or thrombocytopenia

Referral pathway

Referral	When
Hepatology (initial)	Confirm diagnosis, establish UDCA, FibroScan staging, baseline risk stratification
Hepatology (review)	12-month treat-to-target assessment; decision on second-line therapy
Transplant evaluation	Decompensation (ascites, encephalopathy, variceal haemorrhage), jaundice with progression, severe refractory pruritus
Bone metabolism / endocrinology	Osteoporosis on DEXA requiring bisphosphonate
Gastroenterology	Variceal management if portal hypertension

E. Special populations

Pregnancy. UDCA is considered safe throughout pregnancy and is continued — the benefit of preventing disease progression outweighs theoretical risk, and observational data are reassuring. Pre-pregnancy hepatology review is important to optimise liver status, discontinue second-line agents (OCA and bezafibrate require specialist review), and plan surveillance.

Men with PBC. Men comprise approximately 10% of PBC patients but tend to be diagnosed later and with more advanced disease. They carry a higher risk of hepatocellular carcinoma than women with PBC, which changes the surveillance protocol — 6-monthly liver ultrasound plus AFP is recommended for men with PBC even without cirrhosis.

AMA-negative PBC. The clinical course and response to UDCA are the same as AMA-positive disease. sp100 and gp210 antibodies identify the diagnosis; those who are gp210-positive have a worse prognosis and benefit from close hepatology follow-up.

Osteoporosis. The combination of cholestasis (impaired fat-soluble vitamin absorption reducing vitamin D), female sex, and age makes osteoporosis common in PBC. All patients warrant a baseline DEXA scan and vitamin D supplementation; bisphosphonate therapy follows the standard osteoporosis thresholds.

When to escalate

Refer urgently or seek hepatology advice when:

• Confirmed or probable PBC — hepatology referral at diagnosis for FibroScan staging and UDCA initiation
• Jaundice or signs of decompensation — urgent assessment
• Pruritus severe and refractory to first-line cholestyramine — escalate treatment ladder; transplant listing if truly refractory
• ALP not falling on UDCA at 12 months — treat-to-target assessment and second-line decision
• Rising bilirubin or falling albumin — disease progression requiring intensification
• Suspected AIH-PBC overlap (raised ALT and IgG) — histology and combined treatment may be needed

What this article is and is not

This is general health information drawn from Therapeutic Guidelines (eTG), AASLD 2019 practice guidance, EASL 2017 guidelines, the Gastroenterological Society of Australia, and major published trials. It is not personal medical advice and does not replace specialist hepatology input. Decisions about treatment, monitoring frequency, and transplant listing are made between you and your hepatology and GP team.

For consumer resources: HealthDirect — Liver disease, Better Health Channel, GESA — Patient information.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Cholestatic liver disease
2. GESA — Gastroenterological Society of Australia
3. Australian Medicines Handbook (AMH)
4. AASLD 2019 — PBC practice guidance (Lindor, Hepatology 2019)
5. EASL 2017 — PBC clinical practice guidelines
6. BSG 2018 — UK PBC management guidelines
7. Poupon RE et al. — UDCA in PBC (NEJM 1997)
8. Nevens F et al. — POISE trial: OCA in PBC (NEJM 2016)
9. Corpechot C et al. — BEZURSO trial: bezafibrate in PBC (NEJM 2018)
10. Lammers WJ et al. — GLOBE score (Gastroenterology 2015)
11. Carbone M et al. — UK-PBC risk score (J Hepatol 2016)
12. HealthDirect — Liver disease